Unknown

Dataset Information

Comparative efficacy and safety of pharmacological interventions for severe COVID-19 patients: An updated network meta-analysis of 48 randomized controlled trials.


ABSTRACT:

Background

To date, there has been little agreement on what drug is the "best" drug for treating severe COVID-19 patients. This study aimed to assess the efficacy and safety of different medications available at present for severe COVID-19.

Methods

We searched databases for randomized controlled trials (RCTs) published up to February 28, 2022, with no language restrictions, of medications recommended for patients (aged 16 years or older) with severe COVID-19 infection. We extracted data on trials and patient characteristics, and the following primary outcomes: all-cause mortality (ACM), and treatment-emergent adverse events (TEAEs).

Results

We identified 4021 abstracts and of these included 48 RCTs comprising 9147 participants through database searches and other sourc

SUBMITTER: Cheng Q 

PROVIDER: S-EPMC9575403 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature